| 대한안과학회 학술대회 발표 연제 초록 |
| 녹 F-028 |
| 정상안압 녹내장 환자에서 PHP-201에 대한 이중맹검, 무작위 배정, 용량반응 임상2상 시험 |
1. 서울대학교병원 2. 강동경희대학교병원 3. 경북대학교병원 4. 계명대학교 동산병원 5. 부산대학교병원 6. 삼성의료재단 강북삼성병원 7. 연세의료원 세브란스병원 8. 전남대학교병원 9. 충남대학교병원 10. 김안과병원 11. 한양대학교 구리병원 12. 가톨릭대학교 서울성모병원 13. 차의과대학교 분당차병원 14. 국립중앙의료원, 연세의료원 세브란스병원 15. 가천대 길병원 |
| 박기호1, 김영국1, 강자헌2, 김대우3, 이종은4, 이지웅5, 김준모6, 김찬윤7, 박상우8, 김경남9, 김황기10, 성민철11, 박혜영12, 노승수13, 윤상철14, 이종연15 |
목적 : PHP-201 is a small molecule inhibitor of Rho kinase with localized drug action characteristics. This study was conducted to evaluate the reduction of Intraocular Pressure(IOP) and safety of PHP-201 for 4 weeks in patients with normal tension glaucoma (NTG). 방법 : 119 patients with NTG were randomized in 3 groups and treated with PHP-201 in concentrations of 0.25%, 0.5% and Placebo three times daily for 4 weeks. The dose-response of IOP lowering and the incidence of adverse event by PHP-201 and Placebo were investigated. 결과 : The mean baseline IOP was between 15.4 and 15.8mmHg. The mean IOP reductions from the baseline of the last visit in the placebo, 0.25%, and 0.5% group were -0.65mm Hg, -1.10mmHg and -1.56mmHg, respectively. The dose-dependent IOP lowering effect of PHP-201 was statistically significant (p<0.05). Also, conjunctival hyperemia was founded in 1(2.63%) of 38 patients for placebo group, 7(17.5%) of 40 patients for 0.25% group, and 10(24.4%) of 41 patients for 0.5% group. 결론 : PHP-201 0.25% and 0.5% were all effective in lowering the IOP and well tolerated with favorable adverse events including low incidence rate of conjunctival hyperemia. The result suggests that PHP-201 can be a new treatment option for patients with NTG. |